Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study

The authors aimed to evaluate the long-term efficacy and safety of talquetamab, a bispecific antibody targeting GPRC5D, in patients with relapsed/refractory multiple myeloma over a three-year follow-up period from the MonumenTAL-1 study. Results indicated an overall response rate of 67-74% and a median overall survival of 34.0 months, with a manageable safety profile characterized by common adverse events such as cytokine release syndrome and taste changes. The findings suggest that talquetamab provides durable responses and a favorable safety profile compared to existing therapies.